Orlando 407-337-3000
Hablamos tu Idioma
The Villages 352-441-2000

Study

Early Alzheimer’s Combination Therapy Study

Aiming to Hit Alzheimer's with a One-Two Punch

Leqembi Paired With a New Anti-Tau Medication

This early-Alzheimer's combination therapy study looks at whether anti-amyloid and anti-tau medications used together may possibly slow the progression of Alzheimer's disease.

You may have heard about Leqembi (lecanemab) in the news over the past year, that it is one of the latest FDA-approved drugs to help in the fight against Alzheimer’s. Did you know that even though drugs like this are approved for the public, pharmaceutical companies continue to research their benefits? This study looks at the benefits of Leqembi when it’s paired with a new anti-tau investigational drug.

This study is located at our research center in The Villages.

 

Who is eligible?

You may qualify for this study if:

  • You are 50-80 years old.
  • You have a diagnosis of mild Alzheimer's disease.

Sign Up

Schedule Your Assessment

Sign up for an initial assessment (called a “prescreen”), and we'll give you a call. One of our professional medical staff will answer your questions and give you more information about Charter Research prior to an in-office visit.

Get More Information

Your contact information

Do you live in Central Florida?

This field is hidden when viewing the form

Preferred Charter Research location

This field is hidden when viewing the form

I would like to receive the Charter Research newsletter.

I would like to receive text messages from Charter Research for communication purposes.

Comments (not required)

This field is for validation purposes and should be left unchanged.

Location supporting this study

Select Location: